Navigation Links
LSTM-Eisai-UoL awarded GHIT Fund to deliver anti-Wolbachia drug discovery
Date:3/20/2014

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been award a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis. The GHIT Fund facilitates and funds global partnerships for the discovery and development of new health technologies, including drugs, vaccines and diagnostics, for infectious and neglected tropical diseases prevalent in developing countries.

Researchers will aim to identify and develop new drug candidates that efficiently kill the intracellular bacteria Wolbachia living inside the parasitic worms responsible for both lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness) - debilitating infections affecting more than 150 million people globally.

LSTM, through the AWOL Consortium has already shown that a 4-6 week course of the antibiotic doxycycline can deplete Wolbachia from the parasitic worms, leading to worm sterility and slow worm death, thereby breaking the parasitic life-cycle and limiting adverse host immune response. This unique anti-Wolbachia treatment has already been adopted by international health programmes as it has many benefits, including potential for deployment in regions co-endemic with Loa loa and the ability to reduced treatment timeframes compared to standard anti-filarial drugs. However, the use of doxycycline remains limited due to it unsuitability for use in pregnant women and children. To combat these issues, the AWOL Consortium is developing new drugs and discovering new drug candidates that can be used in all populations and with reduced treatment times as short as 7 days. This success was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the GHIT award, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify lead candidate compounds that have a good safety and efficacy profiles ready to move into pre-clinical testing.

With tropical disease expertise led by Prof Steve Ward and Prof Mark Taylor based at LSTM, chemical optimisation of analogues will be performed at Eisai in collaboration with Prof Paul O'Neill's laboratory at the Department of Chemistry, UoL. This unique partnership brings together internationally recognised drug discovery expertise focusing on a novel approach to address the current challenges of two parasitic diseases that affect the lives of many millions of people globally.


'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Kessler Foundation MS scientist awarded Patterson Trust Award in Clinical Research
2. Sloan Research Fellowships awarded to 126 young scholars
3. Director of Womens Guild Lung Institute awarded grant to study treatment for lung disease
4. UC Irvine stem cell researchers awarded $1.54 million in state funding
5. IU School of Medicine researchers awarded $300,000 GE/NFL grant to study concussions
6. UTSA/UTHSCSA awarded $900,000 to prevent substance abuse and HIV/AIDS transmission
7. Mass. Eye and Ear physician awarded RPB Career Development Award
8. Researchers awarded grant from the DeGregorio Family Foundation
9. Obesity Solutions Mexico Directed by Dr. Jose A. Castaneda Awarded 2013's Best Bariatric Surgeon by allPrivateHealth.com
10. Family Voices Awarded Project to Fight Childhood Obesity by the Patient-Centered Outcomes Research Institute
11. Population Council awarded USAID cooperative agreement to develop non-antiretroviral HIV microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: